-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Mereo BioPharma Group, Lowers Price Target to $1

Benzinga·12/29/2025 18:24:05
Listen to the news
BTIG analyst Julian Harrison maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the price target from $6 to $1.